<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1269">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03639987</url>
  </required_header>
  <id_info>
    <org_study_id>221AD205</org_study_id>
    <secondary_id>2018-002102-31</secondary_id>
    <nct_id>NCT03639987</nct_id>
  </id_info>
  <brief_title>A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities</brief_title>
  <acronym>EVOLVE</acronym>
  <official_title>A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Blind, Controlled Study of Aducanumab (BIIB037) in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Subjects With Asymptomatic Amyloid-Related Imaging Abnormalities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the safety impact of continuing aducanumab&#xD;
      dosing in asymptomatic Amyloid-related Imaging Abnormalities (ARIA) in participants with mild&#xD;
      cognitive impairment (MCI) due to Alzheimer's disease (AD) or with mild AD dementia. The&#xD;
      secondary objective of the study is to characterize ARIA, from both the imaging and the&#xD;
      clinical perspective and to characterize the safety, tolerability, pharmacokinetics (PK), and&#xD;
      immunogenicity of aducanumab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was discontinued based on futility analysis conducted on Phase 3 trials (NCT02477800 and&#xD;
    NCT02484547) and not based on safety concerns.&#xD;
  </why_stopped>
  <start_date type="Actual">December 20, 2018</start_date>
  <completion_date type="Actual">July 30, 2019</completion_date>
  <primary_completion_date type="Actual">July 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Clinically Impactful Amyloid-related Imaging Abnormalities (ARIA)</measure>
    <time_frame>up to Week 54</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ARIA by Severity as Obtained on Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>up to Week 54</time_frame>
    <description>ARIA by severity was obtained on Magnetic Resonance Imaging (MRI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of ARIA as Obtained on MRI</measure>
    <time_frame>up to Week 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of ARIA as Obtained on MRI</measure>
    <time_frame>up to Week 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Symptomatic ARIA by Severity</measure>
    <time_frame>up to Week 54</time_frame>
    <description>ARIA by severity was obtained on Magnetic Resonance Imaging (MRI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Symptomatic ARIA</measure>
    <time_frame>up to Week 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Symptomatic ARIA</measure>
    <time_frame>up to Week 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>up to Week 54</time_frame>
    <description>An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose: results in death, in the view of the Investigator, places the participant at immediate risk of death (a life-threatening event), however, this does not include an event that, had it occurred in a more severe form, might have caused death; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect or is a medically important event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Montreal Cognitive Assessment (MoCA) at Week 54</measure>
    <time_frame>Baseline, Week 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Aducanumab Concentration in Serum</measure>
    <time_frame>up to Week 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Antiaducanumab Antibodies in Serum</measure>
    <time_frame>up to Week 54</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Cognitive Dysfunction</condition>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aducanumab, intravenous infusion, every 4 weeks for up to Week 52 during the randomized treatment period. The dose will be titrated to a desirable dose. Participants will be managed for drug continuation and suspension. Following a 4-week follow-up period, eligible participants will continue to receive aducanumab, intravenous infusion, every 4 weeks for an additional 104 weeks in the long-term extension period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aducanumab, intravenous infusion, every 4 weeks for up to Week 52 during the randomized treatment period. The dose will be titrated to a desirable dose. Participants will be managed for drug continuation and suspension. Following a 4-week follow-up period, eligible participants will continue to receive aducanumab, intravenous infusion, every 4 weeks for an additional 104 weeks in the long-term extension period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aducanumab</intervention_name>
    <description>Administered as specified in the treatment arm.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>BIIB037</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered as specified in the treatment arm.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion/ Exclusion Criteria&#xD;
&#xD;
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Ability of the participant or his/her legally authorized representative to understand&#xD;
             the purpose and risks of the study and provide signed and dated informed consent and&#xD;
             authorization to use confidential health information in accordance with national and&#xD;
             local participant privacy regulations.&#xD;
&#xD;
          -  Must have at least 6 years of education or work experience to exclude mental deficits&#xD;
             other than MCI due to AD or mild AD dementia.&#xD;
&#xD;
          -  Must have evidence of cerebral AÎ² accumulation, based on a positive PET scan of the&#xD;
             brain. Previously obtained positron emission tomography (PET) scan (within 12 months&#xD;
             of screening) is permissible. Previous PET scan images must be submitted to the&#xD;
             central imaging vendor to confirm that study inclusion criteria are met.&#xD;
&#xD;
          -  Must consent to apolipoprotein E (ApoE) genotyping.&#xD;
&#xD;
          -  Must meet all of the following clinical criteria for MCI due to AD or mild AD dementia&#xD;
             according to NIA-AA criteria [Albert 2011; McKhann 2011], and must have the following:&#xD;
             MCI due to AD (a CDR global score of 0.5, and an MMSE score between 24 and 30&#xD;
             (inclusive)), or Mild AD dementia (a CDR global score of 0.5 or 1, and as MMSE score&#xD;
             between 20 and 26 (inclusive)).&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Any uncontrolled medical or neurological/neurodegenerative condition (other than AD)&#xD;
             that, in the opinion of the Investigator, might be a contributing cause of the&#xD;
             participant's cognitive impairment (e.g., substance abuse, vitamin B12 deficiency,&#xD;
             abnormal thyroid function, stroke or other cerebrovascular condition, Lewy body&#xD;
             dementia, frontotemporal dementia, head trauma).&#xD;
&#xD;
          -  Clinically significant unstable psychiatric illness (e.g., uncontrolled major&#xD;
             depression, uncontrolled schizophrenia, uncontrolled bipolar affective disorder)&#xD;
             within 6 months prior to Screening.&#xD;
&#xD;
          -  Transient ischemic attack or stroke or any unexplained loss of consciousness within 1&#xD;
             year prior to Screening.&#xD;
&#xD;
          -  Vaccinations within 10 days prior to randomization (Day 1).&#xD;
&#xD;
          -  Female participants who are pregnant or currently breastfeeding.&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner Alzheimer's Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Neurosciences</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Center of North Orange County</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Neuroscience Medical Group</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Research Network, Inc</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Neuroscience Research Medical Group Inc.</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JEM Research Institute</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuropsychiatric Research Center of Southwest Florida</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bioclinica Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bioclinica Orlando</name>
      <address>
        <city>The Villages</city>
        <state>Florida</state>
        <zip>32162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Health and Education Foundation, Inc</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josephson, Wallack, Munshower Neurology, P.C.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Las Vegas Medical Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Memory Research Institute of NJ, PC</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Clinic, PC</name>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <zip>38108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senior Adult Specialty Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78757</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College Of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Network</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research Inc.-Richmond</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingfisher Cooperative, LLC</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Italy</country>
    <country>Spain</country>
  </removed_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 17, 2018</study_first_submitted>
  <study_first_submitted_qc>August 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2018</study_first_posted>
  <results_first_submitted>July 6, 2021</results_first_submitted>
  <results_first_submitted_qc>August 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 16, 2021</results_first_posted>
  <disposition_first_submitted>July 29, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>August 19, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 16, 2021</disposition_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aducanumab</keyword>
  <keyword>BIIB037</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT03639987/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 29, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT03639987/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at 10 investigative sites in the United States from 20 December 2018 to 30 July 2019.</recruitment_details>
      <pre_assignment_details>A total of 52 participants with Alzheimer's disease were enrolled in this study in one of the 2 groups: Group 1 and Group 2 to receive aducanumab titrated up to 10 mg/kg. The groups differed in the protocol specified management rules for amyloid-related imaging abnormalities (ARIA), in the event that moderate or severe asymptomatic ARIA was detected on MRI.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1</title>
          <description>Aducanumab dose titrated up to 10 mg/kg, IV infusion, following Group 1 ARIA management rules.</description>
        </group>
        <group group_id="P2">
          <title>Group 2</title>
          <description>Aducanumab dose titrated up to 10 mg/kg, IV infusion, following Group 2 ARIA management rules.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety population is defined as all randomized participants who had received at least one dose of aducanumab.</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>Aducanumab dose titrated up to 10 mg/kg, IV infusion, following Group 1 ARIA management rules.</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>Aducanumab dose titrated up to 10 mg/kg, IV infusion, following Group 2 ARIA management rules.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.5" spread="7.17"/>
                    <measurement group_id="B2" value="73.3" spread="7.14"/>
                    <measurement group_id="B3" value="72.9" spread="7.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Impactful Amyloid-related Imaging Abnormalities (ARIA)</title>
        <time_frame>up to Week 54</time_frame>
        <population>Clinically Impactful ARIA was to be assessed by an independent Adjudication Committee. At the time the study was terminated, the Adjudication Committee had not been formed; therefore, this outcome measure was not evaluated due to lack of data.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Aducanumab dose titrated up to 10 mg/kg, IV infusion, following Group 1 ARIA management rules.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Aducanumab dose titrated up to 10 mg/kg, IV infusion, following Group 2 ARIA management rules.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Impactful Amyloid-related Imaging Abnormalities (ARIA)</title>
          <population>Clinically Impactful ARIA was to be assessed by an independent Adjudication Committee. At the time the study was terminated, the Adjudication Committee had not been formed; therefore, this outcome measure was not evaluated due to lack of data.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With ARIA by Severity as Obtained on Magnetic Resonance Imaging (MRI)</title>
        <description>ARIA by severity was obtained on Magnetic Resonance Imaging (MRI).</description>
        <time_frame>up to Week 54</time_frame>
        <population>The safety population is defined as all randomized participants who had received at least one dose of aducanumab.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Aducanumab dose titrated up to 10 mg/kg, IV infusion, following Group 1 ARIA management rules.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Aducanumab dose titrated up to 10 mg/kg, IV infusion, following Group 2 ARIA management rules.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ARIA by Severity as Obtained on Magnetic Resonance Imaging (MRI)</title>
          <description>ARIA by severity was obtained on Magnetic Resonance Imaging (MRI).</description>
          <population>The safety population is defined as all randomized participants who had received at least one dose of aducanumab.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of ARIA as Obtained on MRI</title>
        <time_frame>up to Week 54</time_frame>
        <population>Due to small number of ARIA events, data is not reported due to participant confidentiality/human subjects protection assurances.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Aducanumab dose titrated up to 10 mg/kg, IV infusion, following Group 1 ARIA management rules.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Aducanumab dose titrated up to 10 mg/kg, IV infusion, following Group 2 ARIA management rules.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of ARIA as Obtained on MRI</title>
          <population>Due to small number of ARIA events, data is not reported due to participant confidentiality/human subjects protection assurances.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Resolution of ARIA as Obtained on MRI</title>
        <time_frame>up to Week 54</time_frame>
        <population>Due to small number of ARIA events, data is not reported due to participant confidentiality/human subjects protection assurances.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Aducanumab dose titrated up to 10 mg/kg, IV infusion, following Group 1 ARIA management rules.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Aducanumab dose titrated up to 10 mg/kg, IV infusion, following Group 2 ARIA management rules.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of ARIA as Obtained on MRI</title>
          <population>Due to small number of ARIA events, data is not reported due to participant confidentiality/human subjects protection assurances.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Symptomatic ARIA by Severity</title>
        <description>ARIA by severity was obtained on Magnetic Resonance Imaging (MRI).</description>
        <time_frame>up to Week 54</time_frame>
        <population>The safety population is defined as all randomized participants who had received at least one dose of aducanumab.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Aducanumab dose titrated up to 10 mg/kg, IV infusion, following Group 1 ARIA management rules.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Aducanumab dose titrated up to 10 mg/kg, IV infusion, following Group 2 ARIA management rules.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Symptomatic ARIA by Severity</title>
          <description>ARIA by severity was obtained on Magnetic Resonance Imaging (MRI).</description>
          <population>The safety population is defined as all randomized participants who had received at least one dose of aducanumab.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Symptomatic ARIA</title>
        <time_frame>up to Week 54</time_frame>
        <population>Due to small number of ARIA events, data is not reported due to participant confidentiality/human subjects protection assurances.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Aducanumab dose titrated up to 10 mg/kg, IV infusion, following Group 1 ARIA management rules.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Aducanumab dose titrated up to 10 mg/kg, IV infusion, following Group 2 ARIA management rules.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Symptomatic ARIA</title>
          <population>Due to small number of ARIA events, data is not reported due to participant confidentiality/human subjects protection assurances.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Resolution of Symptomatic ARIA</title>
        <time_frame>up to Week 54</time_frame>
        <population>Due to small number of ARIA events, data is not reported due to participant confidentiality/human subjects protection assurances.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Aducanumab dose titrated up to 10 mg/kg, IV infusion, following Group 1 ARIA management rules.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Aducanumab dose titrated up to 10 mg/kg, IV infusion, following Group 2 ARIA management rules.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of Symptomatic ARIA</title>
          <population>Due to small number of ARIA events, data is not reported due to participant confidentiality/human subjects protection assurances.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose: results in death, in the view of the Investigator, places the participant at immediate risk of death (a life-threatening event), however, this does not include an event that, had it occurred in a more severe form, might have caused death; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect or is a medically important event.</description>
        <time_frame>up to Week 54</time_frame>
        <population>The safety population is defined as all randomized participants who had received at least one dose of aducanumab.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Aducanumab dose titrated up to 10 mg/kg, IV infusion, following Group 1 ARIA management rules.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Aducanumab dose titrated up to 10 mg/kg, IV infusion, following Group 2 ARIA management rules.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose: results in death, in the view of the Investigator, places the participant at immediate risk of death (a life-threatening event), however, this does not include an event that, had it occurred in a more severe form, might have caused death; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect or is a medically important event.</description>
          <population>The safety population is defined as all randomized participants who had received at least one dose of aducanumab.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Montreal Cognitive Assessment (MoCA) at Week 54</title>
        <time_frame>Baseline, Week 54</time_frame>
        <population>Due to early termination of the study, none of the participants reached the week 54 timepoint; therefore, data is not available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Aducanumab dose titrated up to 10 mg/kg, IV infusion, following Group 1 ARIA management rules.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Aducanumab dose titrated up to 10 mg/kg, IV infusion, following Group 2 ARIA management rules.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Montreal Cognitive Assessment (MoCA) at Week 54</title>
          <population>Due to early termination of the study, none of the participants reached the week 54 timepoint; therefore, data is not available for analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Aducanumab Concentration in Serum</title>
        <time_frame>up to Week 54</time_frame>
        <population>The safety population is defined as all randomized participants who had received at least one dose of aducanumab.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Aducanumab dose titrated up to 10 mg/kg, IV infusion, following Group 1 ARIA management rules.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Aducanumab dose titrated up to 10 mg/kg, IV infusion, following Group 2 ARIA management rules.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Aducanumab Concentration in Serum</title>
          <population>The safety population is defined as all randomized participants who had received at least one dose of aducanumab.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Antiaducanumab Antibodies in Serum</title>
        <time_frame>up to Week 54</time_frame>
        <population>The safety population is defined as all randomized participants who received at least one dose of aducanumab.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Aducanumab dose titrated up to 10 mg/kg, IV infusion, following Group 1 ARIA management rules.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Aducanumab dose titrated up to 10 mg/kg, IV infusion, following Group 2 ARIA management rules.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Antiaducanumab Antibodies in Serum</title>
          <population>The safety population is defined as all randomized participants who received at least one dose of aducanumab.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Week 54</time_frame>
      <desc>The safety population is defined as all randomized participants who had received at least one dose of aducanumab.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>Aducanumab dose titrated up to 10 mg/kg, IV infusion, following Group 1 ARIA management rules.</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>Aducanumab dose titrated up to 10 mg/kg, IV infusion, following Group 2 ARIA management rules.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was discontinued based on futility analysis conducted on Phase 3 trials (NCT02477800 and NCT02484547). Enrolment and dosing was halted immediately upon the study termination announcement.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>US Biogen Clinical Trial Center</name_or_title>
      <organization>Biogen</organization>
      <phone>866-633-4636</phone>
      <email>clinicaltrials@biogen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

